RBC Capital Reiterates Outperform on Mind Medicine, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams reiterated an Outperform rating on Mind Medicine (NASDAQ:MNMD) and maintained a $5 price target.

June 21, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams reiterated an Outperform rating on Mind Medicine (NASDAQ:MNMD) and maintained a $5 price target.
The reiteration of the Outperform rating and maintenance of the $5 price target by RBC Capital analyst Brian Abrahams indicates a positive outlook for Mind Medicine's stock. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100